Saturday 25 October 2014

Market Snapshot: Cardiac Rhythm Management Devices 2006 to 2020 - US and Europe (US, Germany, France, Italy, UK, Spain), New Report Launched

Market Snapshot: Cardiac Rhythm Management Devices 2006 to 2020

Market Snapshot: Cardiac Rhythm Management Devices 2006 to 2020 - US and Europe (US, Germany, France, Italy, UK, Spain) report provides quantitative analysis of the four cardiac rhythm management devices market segments: : cardiac resynchronization therapy devices, implantable cardioverter defibrillators, implantable loop recorders and pacemakers. The analysis includes market size data by revenue and volume over the 2006–2020 period for the following countries: US, Germany, France, Italy, UK and Spain. It uses data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Publisher’s team of industry experts.

Scope
  • Information on market size for the four cardiac rhythm management devices market segments: cardiac resynchronization therapy devices, implantable cardioverter defibrillators, implantable loop recorders and pacemakers
  • Annualized sales data by revenue for the 2006–2020 period and company share data by revenue for 2013
  • Annualized sales data by volume for the 2006–2020 period
  • Coverage of key geographies: China US, Germany, France, Italy, UK and Spain

Reasons to buy
  • Derive actionable insights from value-volume relationships
  • Analyze value-volume relationships and provide direction to marketing and sales strategies
  • Develop market-entry and market-expansion strategies
  • Identify the key players best positioned to take advantage of opportunities in the US and European markets

Spanning over 78 pages, 116 Tables and 116 Figures Market Snapshot: Cardiac Rhythm Management Devices 2006 to 2020 - US and Europe (US, Germany, France, Italy, UK, Spain)report covering Table of Contents, Definitions, Cardiac Rhythm Management Devices Market, US, Revenue and Volume, 2006–2020, Cardiac Rhythm Management Devices Market, Europe, Revenue, 2006–2020, Cardiac Rhythm Management Devices Market, Germany, Revenue and Volume, 2006–2020, Cardiac Rhythm Management Devices Market, France, Revenue and Volume, 2006–2020, Cardiac Rhythm Management Devices Market, Italy, Revenue and Volume, 2006–2020, Cardiac Rhythm Management Devices Market, UK, Revenue and Volume, 2006–2020, Cardiac Rhythm Management Devices Market, Spain, Revenue and Volume, 2006–2020, Appendix.

Know more about this report athttp://mrr.cm/ZH5

Find all Medical Devices Reports at: http://www.marketresearchreports.com/medical-devices

Tuesday 21 October 2014

Dyslipidemia - Epidemiology Forecast to 2023, New Report Launched

Dyslipidemia - Epidemiology Forecast to 2023

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease, and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial (WHO, 2002). This report provides an overview of the risk factors, comorbidities, and global trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total prevalent cases of dyslipidemia (defined as: elevated low-density lipoprotein cholesterol [LDLc], high triglycerides [TG] [≥200mg/dL], or low levels of high-density lipoprotein cholesterol [HDLc]), as well as the total prevalent cases of increased LDLc (≥115mg/dL to ≥160mg/dL based on country-specific cut-offs), and very high TG (≥500mg/dL), segmented by sex and age (in 10-year intervals beginning at 20 years and ending at ≥70 years). Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) in these markets.

To build the epidemiological forecast for the total prevalent cases of dyslipidemia in the 8MM, Publisher epidemiologists used nationally representative studies that provided the total prevalence of serum lipid disturbances (LDLc, TG, and HDLc) using the National Cholesterol Education Program (NCEP) guidelines for the detection, evaluation, and treatment of high blood cholesterol in adults (part of the Adult Treatment Panel III [ATP III]). To build the epidemiological forecast for the total prevalent cases of FH in the 8MM, Publisher epidemiologists selected the best available studies from peer reviewed journals that provided the total prevalence of FH using the Simon Broome Classification criteria, or the LDLc based criteria. The forecast methodology is consistent across the 8MM, thereby allowing for a meaningful forecast comparison of the total prevalent cases of dyslipidemia as well as the total prevalent cases of FH in these markets.

Publisher epidemiologists forecast that the total prevalent cases of dyslipidemia in the 8MM will increase from 572,418,492 total prevalent cases in 2013, to 685,905,635 total prevalent cases in 2023, at an Annual Growth Rate (AGR) of 1.99%. All markets will see an increase in the total prevalent cases of dyslipidemia at varying AGRs, except for Germany, which will see a decrease. The 8MM had an estimated 3,339,447 total prevalent cases of FH in 2013, and the number of total prevalent cases is expected to increase to 4,365,831 by 2023, at an AGR of 3.07%. All markets will see an increase in the total prevalent cases of FH at varying AGRs, except for Japan, which will see a decrease.

The total prevalent cases of increased LDLc (≥115mg/dL to ≥160mg/dL based on country-specific cut-offs) in the 8MM for 2013 and 2023. Publisher epidemiologists forecast that the total prevalent cases of increased LDLc in the 8MM will increase from 345,008,543 total prevalent cases in 2013 to 411,737,455 total prevalent cases in 2023, at an AGR of 1.93%. All markets will see an increase in the total prevalent cases of increased LDLc at varying AGRs, except for Germany, which will see a decrease. The total prevalent cases of very high TG (≥500mg/dL) in the 8MM for 2013 and 2023. The 8MM had an estimated 10,777,756 total prevalent cases of very high TG in 2013, and the number of total prevalent cases is expected to increase to 12,746,492 by 2023, at an AGR of 1.83%. All markets will see an increase in the total prevalent cases of very high TG at varying AGRs, except for Germany and Japan, which will see a decrease.


Know more about this report athttp://mrr.cm/ZrS

Find all Pharma and Healthcare Report at: - http://www.marketresearchreports.com/pharma-healthcare

Aortic Stent Grafts - Global Analysis and Market Forecasts, New Report Launched

Aortic Stent Grafts - Global Analysis and Market Forecasts

Sales for Aortic Stent Grafts

The total aortic stent graft sales market in 2013 was estimated to be $1,224m across the 10MM.

By the end of the forecast, the stent graft sales market will grow to over $1,930m, with a Compound Annual Growth Rate (CAGR) of 6.7%.

The key drivers for the market in the forecast are:
  • The growing prevalence of aortic aneurysms along with the aging population across the globe with hypertension and obesity.
  • The growing technological advancement in minimally invasive procedures and the desire to eliminate the need for open surgical procedures for aneurysms.
  • The major underserved population for minimally invasive aneurysm treatment in the emerging markets that is driving the procedural numbers up.
  • The unmet need for better clinical outcomes and long-term studies to reduce the risk of endoleaks and other complications.

The US market consists of the largest portion of the aortic stent graft market. The US and European Union (EU) combined formed close to 70% of the global share in 2013. In the remaining markets, Japan is the largest with China and Brazil to follow. India is by far, the smallest market. The EU is technologically the most advanced market, with the best availability of fenestrated and custom stent grafts on the market. The emerging markets see the most open surgical procedures, but stent use is restricted due to the cost of the products and procedures. As training programs for surgeons increase and product prices decrease, the emerging markets will present a strong opportunity for additional revenue for manufacturers. The overall CAGR across all 10 markets is 6.7%, with Japan and China representing the biggest growth opportunities. The growing concerns for multinational companies reside with the need to better target the fast-growing markets and the need to continue to be the leader in development to combat the threat of rising local manufacturers.

Technological Trends

Within the last twenty years, endovascular products have dramatically changed with development relating to improved navigation, trackability, and flexibility, as well as with the stability of access, especially through tortuous anatomy. Imaging technology has had an immense impact on the treatment rates and detection of aneurysms as well. The advances in ultrasound technology have greatly reduced the incidence of aneurysm rupture. Within the emerging markets, these imaging techniques represent an opportunity for stent graft manufacturers to continue training programs for better detecting the aneurysms that are asymptomatic. As a result of better detection, there can be earlier intervention and fewer open surgeries, thereby resulting in more stent graft placement.

The technological developments in endovascular repair will essentially continue to result in positive growth. The primary technological drivers include the development of ultra-low profile systems to access difficult anatomies and arteries that are smaller in diameter, especially in the Asian population. The customized fenestrated products have provided a major opportunity for physicians to treat a new patient pool that was only subject to open repair. As more of these products are approved in the US and other markets, there can be a strong case for greater product adoption. Thoracic endovascular aneurysm repair (TEVAR) is also an area that is still in its infancy, thus yielding low procedure numbers. As there is more development in those product lines and as the abdominal aortic stent graft product matures, there can be a strong platform for development in the abdominal market as well. Generally, there is still much room for development in endovascular aortic repair (EVAR) and TEVAR, and as the products evolve, there will be continued growth in this market.

Unmet Needs Remain a Challenge

The complications in endovascular repair usually occur during or immediately after the procedure, which must be treated immediately through either interventional or open surgery methods. Endoleaks are the most common complication and area of focus; the remaining complications, such as paraplegia, infection, and limb thrombosis, amongst others, occur from time to time and knowledge of them can help enhance future product design.

Technological challenges also pose an opportunity for the development of better products with better clinical outcomes. The availability of lower profile systems will continue to improve accessibility. Customized fenestrated stent grafts will allow more complicated aneurysms to be treated, thereby enhancing the potential patient pool. Multi-branched systems will also allow for more tortuous anatomy to be treated. Finally, addressing the need for more long-term clinical data will allow more surgeons to be comfortable implanting stent grafts, with the assurance of durability in younger patients.

Key Players in the Aortic Stent Graft Market

At present, the aortic stent grafts market is still dominated by the top three players: Cook Medical, Gore Medical, and Medtronic. The products that are currently approved and on the market are all of high quality and each have their strengths with fixation types. The products in development by those outside of the top three players are all innovative in their own way, but a product that will show superior benefits with a lower or at least equal cost will be the one to grow the most.

The most talked about emerging player in the market, based on Publisher’s key opinion leaders (KOLs), is Endologix. Endologix has one of the strongest product pipelines with significantly new product features and a new approach to treatment that has the potential to grab a piece of market share. The next one to three years will determine the quality of the potential products for Endologix, based on approval and clinical trials. Globally, the top 88% of the EVAR market and top 91% in TEVAR market belongs to the three companies mentioned earlier. The emerging markets are still dominated by the top three manufacturers as well, although the emerging markets also have a growing number of local players within Brazil, China, and Japan. India represents the smallest of the emerging markets, with the potential to grow upon lower product prices and an increase of product availability. The ongoing trend in the aortic stent grafts market is that the leading players will continue to maintain market share, unless a disruptive technology in this segment dramatically changes clinical outcomes.

Aortic Stent Graft Market Future Outlook

The economic downturn has been a source of continued concern for high priced medical devices across the global market. The aortic stent grafts market is not one that is excluded from this trend. Despite the high product price, physicians still see a significant benefit in providing endovascular options versus performing open surgery. As physician education improves and they have access to more clinical trial data, the outlook for the aortic stent grafts looks strong with there being much room for product improvement.

The market outlook looks strong in the Western markets, as there is still much room for product adoption and growth. Regionally, one can expect slightly different drivers for growth. The US market is expected to see a significant amount of growth once there is more availability of the customized grafts. In some countries, the EU market is still restricted by cost, thereby making physicians choose their patients carefully before implantation of the device. Finally, the markets such as Japan, China, and Brazil are seeing emerging competition from smaller firms, which will provide a landscape for pressuring large firms to reduce product prices.

The aortic stent grafts market is a moderately growing market at a CAGR of 6.7% globally, with some individual markets boasting a stronger CAGR over others. Within the 10MM, it is the cardiovascular sector that is expected to continue to grow the most in response to the continual technological developments and physicians’ acceptance of the products’ successful clinical performance. The global market is based on, and will be driven by, the rising prevalence of aortic aneurysms and the aging population.

Countries to watch are India and China, but these markets depend heavily on physician comfort with the procedure itself and the availability of new products beyond the major cities and the distribution networks. Publisher expects continued growth in this niche market with the major deterrent, globally, to be product price once a product is accepted by a surgeon.

Know more about this report athttp://mrr.cm/ZrT

Find all Medical Devices Report at: - http://www.marketresearchreports.com/medical-devices

Saturday 18 October 2014

Generic and innovative drugs market in Ukraine 2014: Development forecasts for 2014-2019, New Report Launched

Generic and innovative drugs market in Ukraine 2014: Development forecasts for 2014-2019

This publication is a complete source of fresh data and valuable analysis of essential aspects of the market for generic and innovative medicines in Ukraine. It investigates changing legalities related to the patent process, exclusivity of data and reimbursement and pricing issues.

The report features operational and financial profiles of the selected leading generic and innovative drug companies operating on the Ukrainian market and provides the latest on top-selling preparations and forecasts for growth to 2019.

It also analyses the most influential recent and anticipated market trends and events.

This report provides essential market knowledge, using:
  • Discussion of the pricing and future reimbursement issues for generic and innovative medicines in Ukraine
  • Examination of upcoming changes to prices and possible reimbursements for these preparations
  • Market forecasts for overall development and for each segment over the next five years
  • Value data describing Ukraine’s generic and innovative drugs market
  • Analysis of data exclusivity and patent expiration regulations
  • Analysis of market share occupied by these segments.

Explore key issues on the Ukrainian market for generic and innovative drugs. Report forecasts market development, analyses regulatory changes to 2019.
  • Which are the most influential manufacturers of generic and innovative drugs for the Ukrainian market?
  • What reimbursement policies will most likely influence this market in the near future?
  • Which data exclusivity rules apply to the Ukrainian market for generic and innovative drugs?
  • What is the current and forecast value of this market and its major segments?
  • What are the forecasts for market conditions in Ukraine over the next six years?

Generic and innovative drugs market in Ukraine, development forecasts for 2014-2019 answers these questions along with many others. This publication, compiled by publisher’s team of experienced professionals, offers business information for use in a variety of vital tasks, from evaluating growth prospects to building a more attractive product portfolio.

The report examines changes in the value of the market and major segments from 2009-2014, studies the market share of the Ukrainian pharmaceuticals market currently held by generic and innovative medicines and provides in depth forecasts for market growth and transformation in the years ahead.

The document scrutinises regulations that currently govern pricing and reimbursement of generic and innovative drugs in Ukraine, supplies VAT rates and describes the changes expected with regard to the establishment of the system of the reimbursement. It provides descriptions of the data exclusivity and patent expiration rules and offers analyses of the results of recent changes to industry regulations.
Profiles of top generic and innovative drug producers in Ukraine describe the size, earnings and prospects for each company. Best selling products in each category are named, and patient and physician preferences with regard to generic and innovative medicines are supplied.

Whether businesspeople involved in this industry need to review market regulations particular to Ukraine, check on reimbursement procedures and upcoming changes or estimate demand or growth potential of this market – they will find the informational support needed in this valuable document. It is a remarkable asset when taking business decisions with implications that reach far into the future, such as whether to launch a new business or add a new product line.

Generic and innovative drugs market in Ukraine, development forecasts for 2014-2019 is typically utilised by businesses assessing the market for possible entry, current producers and distributors of generic and innovative drugs for the Ukrainian market and a variety of investment and financial service professionals. Research and consulting professionals also avail themselves of its advantages, along with academic and government institutions, trade and commerce-oriented organizations and business consultants.

Spanning over 100 pages, “Generic and innovative drugs market in Ukraine 2014: Development forecasts for 2014-2019” report covering the Methodology, Characteristics of generic and innovative drugs markets in CIS countries, Generic and innovative drugs market in Ukraine, Best-selling drugs, Reimbursement and pricing policies, Key players, Profiles of key manufacturers.

Know more about this report athttp://mrr.cm/ZKr

Find all Pharma and Healthcare Report at: - http://www.marketresearchreports.com/pharma-healthcare

Generic and innovative drugs market in Russia 2014: Development forecasts for 2014-2019, New Report Launched

Generic and innovative drugs market in Russia 2014: Development forecasts for 2014-2019

This unique publication uses the latest data and analyses of experienced observers to illustrate market potential and describe existing conditions, important trends and events on the market for generic and innovative drugs in Russia. It includes data on the size and market share for each segment and examines the regulatory environment in terms of reimbursement lists, patents, data exclusivity rules and counterfeit medicines.

The report also offers informative profiles of leading companies that sell generic and innovative drugs on the Russian market, lists of best-selling medications and forecasts for the development of each segment to 2019.

Get the freshest data, along with rock solid analyses of:
  • The market share of the generic and innovative drugs segments as related to Russia’s overall pharmaceutical market
  • Expected changes to this market as it develops from 2014-2019
  • Market value data for the period 2011-2015
  • Policies aimed at reducing the quantity of counterfeit drugs sold on the Russian market
  • Reimbursement processes, lists and proposed changes
  • Data exclusivity regulations
  • Patent processes and expirations
  • Allowable price mark ups for generic and innovative drugs sold on the Russian market.

What’s ahead for Russia’s generic and innovative drugs market? Report reveals market value, forecasts for development 2014-2019.
  • How do physicians view the expanding selection of generics and innovative treatments available in Russia?
  • Which company manufactures the largest quantity of generic drugs and innovative treatments for this market?
  • How is pricing determined in this market and how does the Russian reimbursement system work?
  • How long does a patent remain valid in this market?
  • What is the current value of this market and each of its segments? How will these numbers change by 2019?

Readers can find answers to these common market questions, plus many others, in Generic and innovative drugs market in Russia, development forecasts for 2014-2019. This publication combines a broad range of useful data with the analyses of experienced analysts to produce a comprehensive collection of information that will benefit every professional at work in the marketplace.

The report determines the market share of generic and innovative drugs in Russia’s overall pharmaceutical sector. It offers fresh data on market value, overall and for each segment, including historical data captured in recent years.

This document supplies complete coverage of the pricing, markup and reimbursement rules and procedures utilised in the Russian pharmaceutical market for these types of medicines. It includes proposed and planned changes to rules in accordance with the Russian Pharma 2020, a government program that aims to expand domestic manufacturing of generic and innovative drugs and regulate the activity of international producers more closely.

Patent procedures and data exclusivity issues are also explored at length in the pages of this report, which highlights the unique issues that face developers of new generic and innovative treatment options. Additional vital market topics include: top-selling generic and innovative drugs on the Russian market and continued efforts to eliminate the flow of counterfeit products into the market.

Profiles of top manufacturers of generic and innovative drugs for the Russian market are also included in the publication. They provide size, value and location and contact data, as well as plans for new ventures and new product launches.

This publication is essential to planning and operations executives at companies that manufacture generic and innovative drugs for the Russian market. It is a must read for those who need to assess the market in advance of launching a new business or expanding a current one. It is also extremely useful to banking and investment professionals, government employees and business consultants, as well as research specialists and analysts.

Generic and innovative drugs market in Russia, Development forecasts for 2014-2019 is useful when assembling or revising a product portfolio, successfully launching a new business on the market and assessing its potential for investment and growth. It is an irreplaceable resource when studying the changing regulatory situation in this market – it keeps businesspeople updated and knowledgeable of all regulations (and impending changes) that apply to the manufacture and marketing of these new and sought after medicines.

Spanning over 120 pages, “Generic and innovative drugs market in Russia 2014: Development forecasts for 2014-2019” report covering the Methodology, Executive summary, Characteristics of generic and innovative drugs markets in CIS countries, Generic and innovative drugs market in Russia, Profiles of key manufacturers.

Know more about this report athttp://mrr.cm/ZKC

Find all Drug Discovery Report at: - http://www.marketresearchreports.com/drug-discovery

Friday 17 October 2014

Asthma - Pipeline Review, H2 2014, New Report Launched

Asthma - Pipeline Review, H2 2014

Asthma - Pipeline Review, H2 2014 report provides an overview of the Asthma’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Asthma and special features on late-stage and discontinued projects.

Publisher’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Publisher’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Publisher’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Asthma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Asthma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Asthma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products


Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Asthma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Asthma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Spanning over 651 pages, “Asthma - Pipeline Review, H2 2014” report covering the Introduction, Asthma Overview, Therapeutics Development, Drug Profiles, Appendix. The report covered few compnies are - Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Kyowa Hakko Kirin Co., Ltd., Amgen Inc., AstraZeneca PLC, GlaxoSmithKline plc, MedImmune, LLC, Daiichi Sankyo Company, Limited, Merck & Co., Inc.

Know more about this report athttp://mrr.cm/ZKB

Related Reports:

1st - Insulin Resistance - Pipeline Review, H2 2014 - visit at: http://mrr.cm/ZK2

2nd - Huntington's Disease - Pipeline Review, H2 2014 - visit at: http://mrr.cm/ZK6

3rd - Diabetic Neuropathic Pain - Pipeline Review, H2 2014 - visit at: http://mrr.cm/ZKu

Thursday 16 October 2014

Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition), New Report Launched

Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition)

China’s regulatory framework for medical devices is undergoing radical changes. The country’s new leaders have recognized that the regulations for supervision and administration of medical devices are far from perfect along with rapid population growth and thriving economy over the past 30 years. Chinese state council issued the latest “Regulations for the Supervision and Administration of Medical Devices” on February 12, 2014, which has come into force as of June 1, 2014. Before long, China Food and Drug Administration (hereafter called as CFDA) issued the latest “Measures for the Administration of Medical Device Registration”, which has come into force as of October 1, 2014.The overseas medical devices exporting into China market are subject to administration of overall new regulations on medical device registration since October 1, 2014.

In 2009, the Chinese government vigorously launched “China’s Health-Care Reform”, developed an ambitious blueprint, in which health care system covered about 1.2 billion people by 2011. Along with sustained economic and population growth, Chinese healthcare market has maintained annually average growth rate above 16 % since 1990s. Among them, medical devices represented dynamical growth since 2000s. By 2013, total value of medical devices on Chinese healthcare market has reached 179 billion RMB (about 29 billion US dollars). Medical devices have been widely used in the process of disease prevention, diagnosis, therapy, care and rehabilitation. On the Chinese medical device market, imported medical devices made by overseas and multinational medical device manufacturers account for about a half, in which the high-tech and high-valued medical devices, such as magnetic resonance imaging, CT are almost monopolized by GE, Siemens, Philips and other overseas and multinational companies. It is estimated that Chinese medical device market will be likely to be more than 340 billion RMB (about 57 billion US dollars) by 2015, and will surpass Japan to become the second largest medical device market behind the United States. The Chinese medical device market is one of segment market of the most growth potentiality, which is attracting more and more overseas medical device manufacturers and producers to penetrate such market.

China’s radical change of regulatory framework for medical devices brings overseas and multinational medical device manufacturers the maximum challenges and opportunities. Those overseas medical devices have not been granted the certificate of marketing authorization of medical device issued by the government authorities of the country or region of origin have been intercepted outside the door of Chinese clinical trial market not only, and be blocked outside the door of Chinese medical device market also. Nonetheless, Chinese authorities relaxed the admittance license of overseas medical devices. The overseas medical device manufacturer exporting Class I medical devices into China only need to file the archives and the certificate of marketing authorization of the government authorities of the country or region of origin to the CFDA for recordation. The overseas medical device manufacturer exporting Class II and Class III medical devices into China should be subject to be examined and approved by the CFDA. The Chinese authorities will strengthen the supervision and administration for medical devices, including their registration, production, distribution and use. How do you in compliance with the latest Chinese regulations on medical devices? How do you operate business smoothly in China? How do you conduct the clinical evaluation and clinical trial for your products exporting into the Chinese market?

The Chinese concept of clinical evaluation and clinical trial for medical device registration is unique, which is distinct from the clinical trial in U.S. and EU countries.

In China, the process of application and approval for clinical evaluation and clinical trial of imported medical device registration is very complex, because the Chinese medical device authorities administer and control this process by exorbitant administrative measures and regulations, even the guidances. Moreover, these exorbitant administrative measures and regulations, and the guidances are variable and lack of transparency. In addition, the cultural difference between China and Western countries as well as the language barriers will increase the challenge faced by overseas and multinational medical device manufacturers and producers.

To enter such a lucrative medical device market, overseas and multinational medical device manufacturers must have a comprehensive and thorough knowledge of the latest Chinese regulations on medical device clinical evaluation and clinical trial. Otherwise, the restrictive legal requirements and approval delays eat up your development time and budget.

Scope of the report:
Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) not only provided a comprehensive and thorough knowledge of the latest Chinese regulations on clinical evaluation and clinical trial for imported medical device registration but also introduced the practical operation how to comply with the Chinese GCP to guide you use the Chinese trial venues to keep medical device development lean and achieve a successful approval for your products entry into the Chinese medical device market.

The organizations of this guidebook are arranged as follows.
Chapter 2 introduces the framework of the latest Chinese applicable regulations for clinical evaluation and clinical trial of medical device registration to provide a comprehensive and thorough knowledge of the latest Chinese regulations for clinical evaluation and clinical trial of medical device registration.
Chapter 3 provides a comprehensive comparative analysis to tell overseas medical device manufacturer what Chinese regulations on medical device registration are undergoing radical changes, from what Chinese regulations on imported medical device registration are undergoing radical changes to what overseas medical devices need to conduct the clinical evaluation or clinical trial for imported medical device registration.
Chapter 4 provides an overview of the Chinese regulatory authorities -- China Food and Drug Administration (CFDA) being responsible for application and approval for clinical evaluation and clinical trial of imported medical device registration to give the direction of gateway for application for approval of clinical trial of imported overseas medical device registration.
Chapter 5 elaborates the knowledge preparation before consucting the clinical evaluation and clinical trial for imported medical device registration to let overseas medical device manufacturer understand the unique Chinese approach for medical device registration and lay the knowledge foundation for the practical operation.
Chapter 6 elaborates the medical device classification to let overseas medical device manufacturer understand the Chinese medical device classification, because the imported overseas medical device registration must be in compliance with such classification of medical devices.
Chapter 7 introduces the rights of human subjects and every party’s responsibilities in clinical trials for imported overseas medical devices in China.
Chapter 8 introduces the unique Chinese regulations for clinical evaluation and clinical trial of imported medical device registration to help overseas medical device manufacturers to remove their confusion.
Chapter 9 provides the practical guidance for applying for clinical trials of imported overseas medical device registration, from what imported overseas medical devices need to conduct clinical trial and approval within chinese territory, how to apply for clinical trial of imported overseas medical device registration, how to compile the product technical requirements, how to compile application documents to how to acquire the approval document for clinical trial of imported overseas medical device registration to smoothly navigate complex regulatory requirements step by step.
Chapter 10 provides the practical guidance for conducting clinical evaluation of imported overseas medical device registration, also from what imported overseas medical devices need to conduct clinical evaluation of imported overseas medical device registration, what requirements are for conducting clinical evaluation of imported overseas medical device registration, how to conduct the clinical evaluation of imported overseas medical device registration to how to compile application documents to smoothly navigate complex regulatory requirements step by step.
Chapter 11 Appendices provide a complete set of full text in English of the latest Chinese applicable regulations for medical device clinical evaluation and clinical trial of imported overseas medical device registration, which include “Regulations for the Supervision and Administration of Medical Devices (2014 Edition)”, “Measures for the Administration of Medical Device Registration (2014 Edition)”, “Regulations on the Administration of the Instructions and Labels of Medical Devices (2014 Edition)”, “Rules for Medical Device Classification (2014 Edition)” , “Provisions for Clinical Trials of Medical Devices” and “Technical Guidance Principles for Clinical Evaluation of Medical Devices”.

The audiences of this guidebook are overseas medical device manufacturers wishing to enter into the Chinese medical device market, and multinational medical device companies have penetrated into the Chinese medical device market, and their senior executive officers engaging in regulatory affairs expecting to understand how to smoothly conduct clinical evaluation and clinical trial for their medical device product registration in China, and how to comply with the Chinese GCP.

After having skimmed through this guidebook, audiences can clearly acquire not only a comprehensive and thorough knowledge of latest Chinese regulations on clinical evaluation and clinical trial for imported overseas medical device registration but also the practical operation how to comply with the Chinese GCP, how to conduct the clinical evaluation and clinical trial for imported overseas medical device registration. Access China Management Consulting Ltd hopes this guidebook, based on full and accurate laws and regulations, can guide overseas and multinational medical device manufacturers and producers to achieve a successful entry into the Chinese medical device market, and smoothly operate the clinical evaluation and the clinical trial for their products in China.

See this report athttp://mrr.cm/ZKW

Report Highlights:
  • An overview of the latest Chinese applicable regulations for clinical evaluation and clinical trial of medical device registration.
  • A comprehensive comparative analysis ---- what Chinese regulations on medical device registration are undergoing radical changes.
  • An overview of organizational structure of Chinese regulatory authorities for clinical evaluation and clinical trial of imported overseas medical devices registration to give the direction of gateway for application for approval of clinical trial for imported overseas medical device registration.
  • The knowledge preparation before consucting the clinical evaluation and clinical trial for imported overseas medical device registration to let overseas medical device manufacturer understand the unique Chinese approach for medical device registration and lay the knowledge foundation for the practical operation.
  • The detailed Chinese classification for medical devices.
  • The rights of human subjects and every party’s responsibilities in clinical trials for imported overseas medical device registration in China.
  • The unique Chinese regulations for clinical evaluation and clinical trial of imported overseas medical device registration to help overseas medical device manufacturers to remove their confusion.
  • The practical guidance for applying for clinical trials of imported overseas medical device registration, from what imported overseas medical devices need to conduct clinical trial and approval within Chinese territory, how to apply for clinical trial of imported overseas medical device registration, how to compile the product technical requirements, how to compile application documents to how to acquire the approval document for clinical trial of imported overseas medical device registration to smoothly navigate complex regulatory requirements step by step.
  • The practical guidance for conducting clinical evaluation of imported overseas medical device registration, also from what imported overseas medical devices need to conduct clinical evaluation of imported overseas medical device registration, what requirements are for conducting clinical evaluation of imported overseas medical device registration, how to conduct the clinical evaluation of imported overseas medical device registration to how to compile application documents to smoothly navigate complex regulatory requirements step by step.
  • A complete set of full text in English of the latest Chinese applicable regulations for medical device clinical evaluation and clinical trial of imported overseas medical device registration, which include “Regulations for the Supervision and Administration of Medical Devices (2014 Edition)”, “Measures for the Administration of Medical Device Registration (2014 Edition)”, “Regulations on the Administration of the Instructions and Labels of Medical Devices (2014 Edition)”, “Rules for Medical Device Classification (2014 Edition)” , “Provisions for Clinical Trials of Medical Devices” and “Technical Guidance Principles for Clinical Evaluation of Medical Devices”.


Reasons to Buy:
China’s regulatory framework for medical devices is undergoing radical changes. The country’s new leaders have recognized that the regulations for supervision and administration of medical devices are far from perfect along with rapid population growth and thriving economy over the past 30 years. Chinese state council issued the latest “Regulations for the Supervision and Administration of Medical Devices” on February 12, 2014, which has come into force as of June 1, 2014. Before long, China Food and Drug Administration (hereafter called as CFDA) issued the latest “Measures for the Administration of Medical Device Registration”, which has come into force as of October 1, 2014.The overseas medical devices exporting into China market are subject to administration of overall new regulations on medical device registration since October 1, 2014.

The Chinese concept of clinical evaluation and clinical trial for medical device registration is unique, which is distinct from the clinical trial in U.S. and EU countries. How do you in compliance with the latest Chinese regulations on medical devices? How do you operate business smoothly in China? How do you conduct the clinical evaluation and clinical trial for your products exporting into the Chinese market?

To enter such a lucrative medical device market, overseas and multinational medical device manufacturers must have a comprehensive and thorough knowledge of the latest Chinese regulations on medical device clinical evaluation and clinical trial. Otherwise, the restrictive legal requirements and approval delays eat up your development time and budget.

Latest Guidebook for Conducting Medical Device Clinical Evaluation and Clinical Trial in China: From Regulations to Practices (2014 Edition) not only provided a comprehensive and thorough knowledge of the latest Chinese regulations on clinical evaluation and clinical trial for imported medical device registration but also introduced the practical operation how to comply with the Chinese GCP to guide you use the Chinese trial venues to keep medical device development lean and achieve a successful approval for your products entry into the Chinese medical device market.

The overseas medical device manufacturers wishing to enter into the Chinese medical device market, the multinational medical device manufacturers have penetrated into the Chinese medical device market, and their senior executive officers engaging in regulatory affairs for clinical evaluation and clinical trial of exporting overseas medical device into Chinese lucrative medical device market, senior executive officers engaging in applying for approval of exporting overseas medical device registration in China need to understand these latest Chinese registrations and the practical operation. Otherwise, the restrictive legal requirements and approval delays eat up your development time and budget, and cause trouble for your business smoothly in China.

Know more about this report athttp://mrr.cm/ZKW

Find all Medical Devices Report at: - http://www.marketresearchreports.com/medical-devices

Wednesday 15 October 2014

Neonatal Ventilator Market in India - 2014, New Report Launched

Neonatal Ventilator Market in India - 2014

This report provides an insight into the Neonatal Ventilator current market scenario, structure and practices in India.

In depth market scenario includes;
  • Market estimate of Neonatal Ventilator in India for FY14
  • Geographical presence of key players in India
  • Providing insights into Industry drivers and challenges and their impact on the future market
  • Regulatory bodies and their roles
  • Future Market projections for 5 years
  • Opportunities in the Industry

Spanning over 25 pages “Neonatal Ventilator Market in India - 2014” report covering Background, Scope of this research, Research aim and objectives, Research methodology, Industry Snapshot, Industry Structure, Major Clusters, Growth Drivers, Issues and Challenges, Prevailing Govt. Policies, Future Outlook, Key Opportunities, Key Players Snapshot. This Report Covered Many Companies Few are - Modular Dental Equipments, S.K. Dent India, Narang Medical Limited, Novo Dental Products Pvt. Ltd., Dentomed Health Care, Phoenix Dental Equipments Pvt. Ltd., Bestodent India Pvt. Ltd., D.H.A Enterprises, Tulja Dental & Medical Equipment Pvt. Ltd.

Know more about this report athttp://mrr.cm/ZK5

Opportunity in Biotechnology Industry in India - 2014, New Report Launched

Opportunity in Biotechnology Industry in India - 2014

This report provides an insight into the Opportunity in Biotechnology Industry current scenario, structure and practices in India.

In depth market scenario includes;
  • Current market size estimates
  • Market size by players – Top Companies
  • Market size by product categories - Bio-Pharma, Bio-Services, Bio-Agri, Bio-Industrial, Bio-Informatics
  • Market size by end user segments – Agriculture, Healthcare, Chemicals, Food Industry, Pharmaceutical
  • Market size by regions – North, South, East, West


Market structure details the value chain key players’ presence across products and end user segments. Market practices include understanding the Opportunity in Biotechnology Industry sets business and market trends.

The report also provides a snapshot of key competition, past market trends with forecast over the next 5 years, anticipated growth rates and the principal factors driving and impacting growth.

Market data and analytics are derived from a combination of primary and secondary sources.

Spanning over 45 pages, “Opportunity in Biotechnology Industry in India - 2014” report covering the Background, Executive Summary, Market Overview, Estimate of Market Size in India, Market Share Estimates, Factors Impacting Market Growth, Market Forecast, Snapshot of Key Players.

Know more about this report athttp://mrr.cm/ZzD

Find all Pharma and Healthcare Reports at: http://www.marketresearchreports.com/pharma-healthcare

Related Reports at:

1st - Opportunity in the Indian Ventilator Market - 2014 visit at: http://mrr.cm/Zzz

2nd - Clinical Trails Market in India – 2014 visit at: http://mrr.cm/ZzK